- Report
- March 2024
- 188 Pages
Global
From €3243EUR$3,374USD£2,781GBP
€3603EUR$3,749USD£3,090GBP
- Report
- October 2023
- 190 Pages
Global
From €4710EUR$4,900USD£4,039GBP
- Report
- April 2023
- 110 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- July 2020
- 1740 Pages
Global
From €4614EUR$4,800USD£3,956GBP
- Report
- May 2024
- 50 Pages
Global
From €2547EUR$2,650USD£2,184GBP
Cladribine is a drug used to treat certain types of leukemia, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It is a purine nucleoside analog, which works by interfering with the growth of cancer cells. Cladribine is typically administered intravenously or subcutaneously, and is available in both tablet and injection form.
Cladribine is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2018. It is currently marketed by several pharmaceutical companies, including Merck, Novartis, and Teva Pharmaceuticals.
The cladribine market is highly competitive, with several companies vying for market share. Companies are investing heavily in research and development to create new and improved versions of the drug, as well as to expand its use to other types of leukemia. Additionally, companies are focusing on increasing access to the drug, as well as providing patient support services.
Companies in the cladribine market include Merck, Novartis, Teva Pharmaceuticals, Celgene, and Gilead Sciences. Show Less Read more
